REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
09/01/2025
Back to search
Official data from USPTO
ROVIPIA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
09/02/2025
Trademark type
Word
Nice classes
5, 44
Filing date
12/02/2019
Registration date
09/01/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/01/2020
Last transaction
09/02/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
25
Owner location
CH
Examiner
CORNWELL, ANDREA
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NOVARTIS AG
Representatives
Maury M. Tepper, III Tepper & Eyster, PLLC
Technical classification
Nice Classes
Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; biological preparations for the treatment of bacterial infectionsviral infectionsinflammatory disordersfungal infectionscardiovascular diseases and disordersdermatological conditionsrespiratory diseases and disorderscentral nervous system diseases and disordersgastrointestinal diseases and disorderskidney diseasesdiabeteshypertensionskin disorderscancer and tumorsallergiesbone diseasesdiseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe Musculo-skeletal system and the genitourinary system; biological preparations for use in hematology and in tissue and organ transplantation; biological preparations for prevention and treatment of eye diseases and conditions; biological preparations for the prevention and treatment of heart rhythm disorders; biological preparations for the prevention and treatment of immune system related diseases and disorders and stem cells for pharmaceutical and medical use
Class 44
Collection and preservation of blood; collection and preservation services for tissue and cellscollection and banking of umbilical cord tissue perivascular stem cells; medical diagnostic services; medical treatment services; provision of medical information and data for diagnosis and medical treatment
Publications
History of USPTO decisions and trademark events.
30 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/23/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/31/2020
FIMP
FINAL DISPOSITION PROCESSED
12/31/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/01/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
09/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/16/2020
PUBO
PUBLISHED FOR OPPOSITION
06/16/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/27/2020
ALIE
ASSIGNED TO LIE
05/07/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/29/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/24/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/23/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/23/2020
RFNT
REFUSAL PROCESSED BY IB
04/10/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/18/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/18/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/18/2020
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/18/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/18/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/18/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/18/2020
RFRR
REFUSAL PROCESSED BY MPU
03/18/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/28/2020
CNRT
NON-FINAL ACTION WRITTEN
02/27/2020
DOCK
ASSIGNED TO EXAMINER
02/27/2020
MAFR
APPLICATION FILING RECEIPT MAILED
02/18/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/12/2020
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
02/11/2020
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
02/06/2020
Continuous trademark protection
Get notified about every new filing that threatens ROVIPIA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.